CD8A and neoplasm: To assess whether CD4+ and CD8α+ T-cells are drivers in the eMSC treatment effect, these subpopulations were each separately depleted in 4T1 tumor-bearing mice through specific antibodies followed by eMSC or sham-treatment (Figure 5A).